TY - JOUR AU - Kim, R. AU - Emi, M. AU - Tanabe, K. PY - 2017 DA - 2017// TI - Cancer immunoediting from immune surveillance to immune escape JO - Immunology VL - 121 UR - https://doi.org/10.1111/j.1365-2567.2007.02587.x DO - 10.1111/j.1365-2567.2007.02587.x ID - Kim2017 ER - TY - JOUR AU - Eisenhauer, E. A. AU - Therasse, P. AU - Bogaerts, J. PY - 2009 DA - 2009// TI - New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) JO - Eur J Cancer VL - 45 UR - https://doi.org/10.1016/j.ejca.2008.10.026 DO - 10.1016/j.ejca.2008.10.026 ID - Eisenhauer2009 ER - TY - STD TI - Raja J, Ludwig JM, Gettinger SN, Schalper KA, Kim HS (2018) Oncolytic virus immunotherapy: future prospects for oncology. J Immunother Cancer 6:140. https://doi.org/10.1186/s40425-018-0458-z ID - ref3 ER - TY - JOUR AU - Andtbacka, R. H. AU - Kaufman, H. L. AU - Collichio, F. PY - 2015 DA - 2015// TI - Talimogene laherparepvec improves durable response rate in patients with advanced melanoma JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.58.3377 DO - 10.1200/JCO.2014.58.3377 ID - Andtbacka2015 ER - TY - JOUR AU - Raman, S. S. AU - Hecht, J. R. AU - Chan, E. PY - 2019 DA - 2019// TI - Talimogene laherparepvec: review of its mechanism of action and clinical efficacy and safety JO - Immunotherapy VL - 11 UR - https://doi.org/10.2217/imt-2019-0033 DO - 10.2217/imt-2019-0033 ID - Raman2019 ER - TY - JOUR AU - Hollingsworth, R. E. AU - Jansen, K. PY - 2019 DA - 2019// TI - Turning the corner on therapeutic cancer vaccines JO - NPJ Vaccines VL - 4 UR - https://doi.org/10.1038/s41541-019-0103-y DO - 10.1038/s41541-019-0103-y ID - Hollingsworth2019 ER - TY - JOUR AU - Schuler, G. AU - Schuler-Thurner, B. AU - Steinman, R. M. PY - 2003 DA - 2003// TI - The use of dendritic cells in cancer immunotherapy JO - Curr Opin Immunol VL - 15 UR - https://doi.org/10.1016/s0952-7915(03)00015-3 DO - 10.1016/s0952-7915(03)00015-3 ID - Schuler2003 ER - TY - JOUR AU - Bol, K. F. AU - Schreibelt, G. AU - Rabold, K. PY - 2019 DA - 2019// TI - The clinical application of cancer immunotherapy based on naturally circulating dendritic cells JO - J Immunother Cancer VL - 7 UR - https://doi.org/10.1186/s40425-019-0580-6 DO - 10.1186/s40425-019-0580-6 ID - Bol2019 ER - TY - JOUR AU - Pilon-Thomas, S. AU - Kuhn, L. AU - Ellwanger, S. PY - 2012 DA - 2012// TI - Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma JO - J Immunother VL - 35 UR - https://doi.org/10.1097/CJI.0b013e31826e8f5f DO - 10.1097/CJI.0b013e31826e8f5f ID - Pilon-Thomas2012 ER - TY - JOUR AU - Prasad, V. PY - 2018 DA - 2018// TI - Immunotherapy: tisagenlecleucel - the first approved CAR-T-cell therapy: implications for payers and policy makers JO - Nat Rev Clin Oncol VL - 15 UR - https://doi.org/10.1038/nrclinonc.2017 DO - 10.1038/nrclinonc.2017 ID - Prasad2018 ER - TY - JOUR AU - Jackson, H. J. AU - Rafiq, S. AU - Brentjens, R. J. PY - 2016 DA - 2016// TI - Driving CAR T-cells forward JO - Nat Rev Clin Oncol VL - 13 UR - https://doi.org/10.1038/nrclinonc.2016.36 DO - 10.1038/nrclinonc.2016.36 ID - Jackson2016 ER - TY - JOUR AU - Wei, S. C. AU - Duffy, C. R. AU - Allison, J. P. PY - 2018 DA - 2018// TI - Fundamental mechanisms of immune checkpoint blockade therapy JO - Cancer Discov VL - 8 UR - https://doi.org/10.1158/2159-8290.CD-18-0367 DO - 10.1158/2159-8290.CD-18-0367 ID - Wei2018 ER - TY - STD TI - Approved immunotherapies. Medi paper available from: https://medi-paper.com/us-fda-approved-immune-checkpoint-inhibitors-approved-immunotherapies/. Accessed Oct 26, 2019 UR - https://medi-paper.com/us-fda-approved-immune-checkpoint-inhibitors-approved-immunotherapies/ ID - ref13 ER - TY - JOUR AU - Madan, R. A. AU - Gulley, J. L. AU - Fojo, T. AU - Dahut, W. L. PY - 2010 DA - 2010// TI - Therapeutic Cancer Vaccines in Prostate Cancer: The Paradox of Improved Survival Without Changes in Time to Progression JO - The Oncologist VL - 15 UR - https://doi.org/10.1634/theoncologist.2010-0129 DO - 10.1634/theoncologist.2010-0129 ID - Madan2010 ER - TY - JOUR AU - Kaech, S. M. AU - Wherry, E. J. AU - Ahmed, R. PY - 2002 DA - 2002// TI - Effector and memory T-cell differentiation: implications for vaccine development JO - Nat Rev Immunol VL - 2 UR - https://doi.org/10.1038/nri778 DO - 10.1038/nri778 ID - Kaech2002 ER - TY - STD TI - Xiang R, Lode HN, Gillies SD, Reisfeld RA (1999) T cell memory against colon carcinoma is long-lived in the absence of antigen. J Immunol 163:3676–3683 ID - ref16 ER - TY - JOUR AU - Wolchok, J. D. AU - Hoos, A. AU - O'Day, S. PY - 2009 DA - 2009// TI - Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria JO - Clin Cancer Res VL - 15 UR - https://doi.org/10.1158/1078-0432.CCR-09-1624 DO - 10.1158/1078-0432.CCR-09-1624 ID - Wolchok2009 ER - TY - JOUR AU - Larkin, J. AU - Minor, D. AU - D'Angelo, S. PY - 2018 DA - 2018// TI - Overall survival in patients with advanced melanoma who received nivolumab versus investigator’s choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2016.71.8023 DO - 10.1200/JCO.2016.71.8023 ID - Larkin2018 ER - TY - JOUR AU - Robert, C. AU - Ribas, A. AU - Hamid, O. PY - 2018 DA - 2018// TI - Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2017.75.6270 DO - 10.1200/JCO.2017.75.6270 ID - Robert2018 ER - TY - JOUR AU - Horn, L. AU - Spigel, D. R. AU - Vokes, E. E. PY - 2017 DA - 2017// TI - Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057) JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2017.74.3062 DO - 10.1200/JCO.2017.74.3062 ID - Horn2017 ER - TY - JOUR AU - Haslam, A. AU - Prasad, V. PY - 2019 DA - 2019// TI - Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs JO - JAMA Netw Open VL - 2 UR - https://doi.org/10.1001/jamanetworkopen.2019.2535 DO - 10.1001/jamanetworkopen.2019.2535 ID - Haslam2019 ER - TY - JOUR AU - Giacomo, A. M. AU - Danielli, R. AU - Guidoboni, M. PY - 2009 DA - 2009// TI - Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases JO - Cancer Immunol Immunother VL - 58 UR - https://doi.org/10.1007/s00262-008-0642-y DO - 10.1007/s00262-008-0642-y ID - Giacomo2009 ER - TY - JOUR AU - Gainor, J. F. AU - Longo, D. L. AU - Chabner, B. A. PY - 2014 DA - 2014// TI - Pharmacodynamic Biomarkers: Falling Short of the Mark? JO - Clinical Cancer Research VL - 20 UR - https://doi.org/10.1158/1078-0432.CCR-13-3132 DO - 10.1158/1078-0432.CCR-13-3132 ID - Gainor2014 ER - TY - JOUR AU - Nishino, M. i. z. u. k. i. AU - Giobbie-Hurder, A. n. i. t. a. AU - Manos, M. i. c. h. a. e. l. P. AU - Bailey, N. a. n. c. y. AU - Buchbinder, E. l. i. z. a. b. e. t. h. I. AU - Ott, P. a. t. r. i. c. k. A. AU - Ramaiya, N. i. k. h. i. l. H. AU - Hodi, F. S. t. e. p. h. e. n. PY - 2017 DA - 2017// TI - Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions JO - Clinical Cancer Research VL - 23 UR - https://doi.org/10.1158/1078-0432.CCR-17-0114 DO - 10.1158/1078-0432.CCR-17-0114 ID - Nishino2017 ER - TY - JOUR AU - Thust, S. C. AU - Bent, M. J. AU - Smits, M. PY - 2018 DA - 2018// TI - Pseudoprogression of brain tumors JO - J Magn Reson Imaging VL - 48 UR - https://doi.org/10.1002/jmri.26171 DO - 10.1002/jmri.26171 ID - Thust2018 ER - TY - JOUR AU - Hodi, F. S. AU - Hwu, W. J. AU - Kefford, R. PY - 2016 DA - 2016// TI - Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2015.64.0391 DO - 10.1200/JCO.2015.64.0391 ID - Hodi2016 ER - TY - JOUR AU - Fujimoto, D. AU - Yoshioka, H. AU - Kataoka, Y. PY - 2019 DA - 2019// TI - Pseudoprogression in previously treated patients with non-small cell lung cancer who received nivolumab monotherapy JO - J Thorac Oncol VL - 14 UR - https://doi.org/10.1016/j.jtho.2018.10.167 DO - 10.1016/j.jtho.2018.10.167 ID - Fujimoto2019 ER - TY - JOUR AU - Champiat, S. AU - Ferrara, R. AU - Massard, C. PY - 2018 DA - 2018// TI - Hyperprogressive disease: recognizing a novel pattern to improve patient management JO - Nat Rev Clin Oncol VL - 15 UR - https://doi.org/10.1038/s41571-018-0111-2 DO - 10.1038/s41571-018-0111-2 ID - Champiat2018 ER - TY - JOUR AU - Ferrara, R. o. b. e. r. t. o. AU - Mezquita, L. a. u. r. a. AU - Texier, M. a. t. t. h. i. e. u. AU - Lahmar, J. i. h. e. n. e. AU - Audigier-Valette, C. l. a. r. i. s. s. e. AU - Tessonnier, L. a. u. r. e. n. t. AU - Mazieres, J. u. l. i. e. n. AU - Zalcman, G. e. r. a. r. d. AU - Brosseau, S. o. l. e. n. n. AU - Le Moulec, S. y. l. v. e. s. t. r. e. AU - Leroy, L. a. u. r. a. AU - Duchemann, B. o. r. i. s. AU - Lefebvre, C. o. r. e. n. t. i. n. AU - Veillon, R. e. m. i. AU - Westeel, V. i. r. g. i. n. i. e. AU - Koscielny, S. e. r. g. e. AU - Champiat, S. t. e. p. h. a. n. e. AU - Ferté, C. h. a. r. l. e. s. AU - Planchard, D. a. v. i. d. AU - Remon, J. o. r. d. i. AU - Boucher, M. a. r. i. e. -. E. v. e. AU - Gazzah, A. n. a. s. AU - Adam, J. u. l. i. e. n. AU - Bria, E. m. i. l. i. o. AU - Tortora, G. i. a. m. p. a. o. l. o. AU - Soria, J. e. a. n. -. C. h. a. r. l. e. s. AU - Besse, B. e. n. j. a. m. i. n. AU - Caramella, C. a. r. o. l. i. n. e. PY - 2018 DA - 2018// TI - Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy JO - JAMA Oncology VL - 4 UR - https://doi.org/10.1001/jamaoncol.2018.3676 DO - 10.1001/jamaoncol.2018.3676 ID - Ferrara2018 ER - TY - JOUR AU - Demicheli, R. AU - Retsky, M. W. AU - Hrushesky, W. J. M. AU - Baum, M. AU - Gukas, I. D. PY - 2008 DA - 2008// TI - The effects of surgery on tumor growth: a century of investigations JO - Annals of Oncology VL - 19 UR - https://doi.org/10.1093/annonc/mdn386 DO - 10.1093/annonc/mdn386 ID - Demicheli2008 ER - TY - JOUR AU - Lagadec, C. h. a. n. n. AU - Vlashi, E. r. i. n. a. AU - Della Donna, L. o. r. e. n. z. a. AU - Dekmezian, C. a. r. m. e. n. AU - Pajonk, F. r. a. n. k. PY - 2012 DA - 2012// TI - Radiation-Induced Reprogramming of Breast Cancer Cells JO - STEM CELLS VL - 30 UR - https://doi.org/10.1002/stem.1058 DO - 10.1002/stem.1058 ID - Lagadec2012 ER - TY - JOUR AU - Miller, A. B. AU - Hoogstraten, B. AU - Staquet, M. AU - Winkler, A. PY - 1981 DA - 1981// TI - Reporting results of cancer treatment JO - Cancer VL - 47 UR - https://doi.org/3.0.CO;2-6 DO - 3.0.CO;2-6 ID - Miller1981 ER - TY - JOUR AU - Nishino, M. AU - Giobbie-Hurder, A. AU - Gargano, M. AU - Suda, M. AU - Ramaiya, N. H. AU - Hodi, F. S. PY - 2013 DA - 2013// TI - Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements JO - Clinical Cancer Research VL - 19 UR - https://doi.org/10.1158/1078-0432.CCR-13-0895 DO - 10.1158/1078-0432.CCR-13-0895 ID - Nishino2013 ER - TY - JOUR AU - Seymour, L. AU - Bogaerts, J. AU - Perrone, A. PY - 2017 DA - 2017// TI - iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics JO - Lancet Oncol VL - 18 UR - https://doi.org/10.1016/S1470-2045(17)30074-8 DO - 10.1016/S1470-2045(17)30074-8 ID - Seymour2017 ER - TY - JOUR AU - Hodi, F. S. AU - Ballinger, M. AU - Lyons, B. PY - 2018 DA - 2018// TI - Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): refining guidelines to assess the clinical benefit of cancer immunotherapy JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2017.75.1644 DO - 10.1200/JCO.2017.75.1644 ID - Hodi2018 ER - TY - JOUR AU - Kataoka, Y. AU - Hirano, K. PY - 2018 DA - 2018// TI - Which criteria should we use to evaluate the efficacy of immune-checkpoint inhibitors? JO - Ann Transl Med VL - 6 UR - https://doi.org/10.21037/atm.2018.04.17 DO - 10.21037/atm.2018.04.17 ID - Kataoka2018 ER - TY - JOUR AU - Postow, M. A. AU - Sidlow, R. AU - Hellmann, M. D. PY - 2018 DA - 2018// TI - Immune-related adverse events associated with immune checkpoint blockade JO - N Engl J Med VL - 378 UR - https://doi.org/10.1056/NEJMra1703481 DO - 10.1056/NEJMra1703481 ID - Postow2018 ER - TY - JOUR AU - Haanen, J. B. A. G. AU - Carbonnel, F. AU - Robert, C. AU - Kerr, K. M. AU - Peters, S. AU - Larkin, J. AU - Jordan, K. PY - 2018 DA - 2018// TI - Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up JO - Annals of Oncology VL - 29 UR - https://doi.org/10.1093/annonc/mdy162 DO - 10.1093/annonc/mdy162 ID - Haanen2018 ER - TY - JOUR AU - Martins, F. AU - Sofiya, L. AU - Sykiotis, G. P. PY - 2019 DA - 2019// TI - Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance JO - Nat Rev Clin Oncol VL - 16 UR - https://doi.org/10.1038/s41571-019-0218-0 DO - 10.1038/s41571-019-0218-0 ID - Martins2019 ER - TY - JOUR AU - Wang, P. F. AU - Chen, Y. AU - Song, S. Y. PY - 2017 DA - 2017// TI - Immune-related adverse events associated with anti-PD-1/PD-L1 treatment for malignancies: a meta-analysis JO - Front Pharmacol VL - 8 UR - https://doi.org/10.3389/fphar.2017.00730 DO - 10.3389/fphar.2017.00730 ID - Wang2017 ER - TY - JOUR AU - Sun, X. AU - Roudi, R. AU - Dai, T. PY - 2019 DA - 2019// TI - Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis JO - BMC Cancer VL - 19 UR - https://doi.org/10.1186/s12885-019-5701-6 DO - 10.1186/s12885-019-5701-6 ID - Sun2019 ER - TY - STD TI - Bertrand A, Kostine M, Barnetche T, Truchetet ME, Schaeverbeke T (2015) Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med 13:211. https://doi.org/10.1186/s12916-015-0455-8 ID - ref42 ER - TY - JOUR AU - Nishino, M. AU - Hatabu, H. AU - Hodi, F. S. PY - 2019 DA - 2019// TI - Imaging of cancer immunotherapy: current approaches and future directions JO - Radiology VL - 290 UR - https://doi.org/10.1148/radiol.2018181349 DO - 10.1148/radiol.2018181349 ID - Nishino2019 ER - TY - JOUR AU - Bronstein, Y. u. l. i. a. AU - Ng, C. h. a. a. n. S. AU - Hwu, P. a. t. r. i. c. k. AU - Hwu, W. e. n. -. J. e. n. PY - 2011 DA - 2011// TI - Radiologic Manifestations of Immune-Related Adverse Events in Patients With Metastatic Melanoma Undergoing Anti–CTLA-4 Antibody Therapy JO - American Journal of Roentgenology VL - 197 UR - https://doi.org/10.2214/AJR.10.6198 DO - 10.2214/AJR.10.6198 ID - Bronstein2011 ER - TY - JOUR AU - Carter, B. r. e. t. t. W. AU - Halpenny, D. a. r. r. a. g. h. F. AU - Ginsberg, M. i. c. h. e. l. l. e. S. AU - Papadimitrakopoulou, V. a. s. s. i. l. i. k. i. A. AU - de Groot, P. a. t. r. i. c. i. a. M. PY - 2017 DA - 2017// TI - Immunotherapy in Non–Small Cell Lung Cancer Treatment JO - Journal of Thoracic Imaging VL - 32 UR - https://doi.org/10.1097/RTI.0000000000000291 DO - 10.1097/RTI.0000000000000291 ID - Carter2017 ER - TY - JOUR AU - Kwak, J. e. n. n. i. f. e. r. J. AU - Tirumani, S. r. e. e. H. a. r. s. h. a. AU - Van den Abbeele, A. n. n. i. c. k. D. AU - Koo, P. h. i. l. l. i. p. J. AU - Jacene, H. e. a. t. h. e. r. A. PY - 2015 DA - 2015// TI - Cancer Immunotherapy: Imaging Assessment of Novel Treatment Response Patterns and Immune-related Adverse Events JO - RadioGraphics VL - 35 UR - https://doi.org/10.1148/rg.352140121 DO - 10.1148/rg.352140121 ID - Kwak2015 ER - TY - JOUR AU - Tirumani, S. H. AU - Ramaiya, N. H. AU - Keraliya, A. PY - 2015 DA - 2015// TI - Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab JO - Cancer Immunol Res VL - 3 UR - https://doi.org/10.1158/2326-6066.CIR-15-0102 DO - 10.1158/2326-6066.CIR-15-0102 ID - Tirumani2015 ER - TY - JOUR AU - Wang, G. X. AU - Kurra, V. AU - Gainor, J. F. PY - 2017 DA - 2017// TI - Immune checkpoint inhibitor cancer therapy: spectrum of imaging findings JO - Radiographics VL - 37 UR - https://doi.org/10.1148/rg.2017170085 DO - 10.1148/rg.2017170085 ID - Wang2017 ER - TY - JOUR AU - Gupta, A. AU - De Felice, K. M. AU - Loftus, E. V. AU - Khanna, S. PY - 2015 DA - 2015// TI - Systematic review: colitis associated with anti-CTLA-4 therapy JO - Alimentary Pharmacology & Therapeutics VL - 42 UR - https://doi.org/10.1111/apt.13281 DO - 10.1111/apt.13281 ID - Gupta2015 ER - TY - JOUR AU - Alessandrino, F. AU - Sahu, S. AU - Nishino, M. PY - 2019 DA - 2019// TI - Frequency and imaging features of abdominal immune-related adverse events in metastatic lung cancer patients treated with PD-1 inhibitor JO - Abdom Radiol (NY) VL - 44 UR - https://doi.org/10.1007/s00261-019-01935-2 DO - 10.1007/s00261-019-01935-2 ID - Alessandrino2019 ER - TY - JOUR AU - Kim, K. W. AU - Ramaiya, N. H. AU - Krajewski, K. M. PY - 2013 DA - 2013// TI - Ipilimumab associated hepatitis: imaging and clinicopathologic findings JO - Invest New Drugs VL - 31 UR - https://doi.org/10.1007/s10637-013-9939-6 DO - 10.1007/s10637-013-9939-6 ID - Kim2013 ER - TY - JOUR AU - Raad, R. o. y. A. AU - Pavlick, A. n. n. a. AU - Kannan, R. a. j. n. i. AU - Friedman, K. e. n. t. P. PY - 2015 DA - 2015// TI - Ipilimumab-Induced Hepatitis on 18F-FDG PET/CT in a Patient With Malignant Melanoma JO - Clinical Nuclear Medicine VL - 40 UR - https://doi.org/10.1097/RLU.0000000000000606 DO - 10.1097/RLU.0000000000000606 ID - Raad2015 ER - TY - JOUR AU - Alabed, Y. a. z. a. n. Z. AU - Aghayev, A. y. a. z. AU - Sakellis, C. h. r. i. s. t. o. p. h. e. r. AU - Van den Abbeele, A. n. n. i. c. k. D. PY - 2015 DA - 2015// TI - Pancreatitis Secondary to Anti–Programmed Death Receptor 1 Immunotherapy Diagnosed by FDG PET/CT JO - Clinical Nuclear Medicine VL - 40 UR - https://doi.org/10.1097/RLU.0000000000000940 DO - 10.1097/RLU.0000000000000940 ID - Alabed2015 ER - TY - JOUR AU - Faje, A. T. AU - Sullivan, R. AU - Lawrence, D. PY - 2014 DA - 2014// TI - Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma JO - J Clin Endocrinol Metab VL - 99 UR - https://doi.org/10.1210/jc.2014-2306 DO - 10.1210/jc.2014-2306 ID - Faje2014 ER - TY - JOUR AU - Alessandrino, F. AU - Shah, H. J. AU - Ramaiya, N. H. PY - 2018 DA - 2018// TI - Multimodality imaging of endocrine immune related adverse events: a primer for radiologists JO - Clin Imaging VL - 50 UR - https://doi.org/10.1016/j.clinimag.2017.12.014 DO - 10.1016/j.clinimag.2017.12.014 ID - Alessandrino2018 ER - TY - JOUR AU - Carpenter, K. J. AU - Murtagh, R. D. AU - Lilienfeld, H. AU - Weber, J. AU - Murtagh, F. R. PY - 2009 DA - 2009// TI - Ipilimumab-Induced Hypophysitis: MR Imaging Findings JO - American Journal of Neuroradiology VL - 30 UR - https://doi.org/10.3174/ajnr.A1623 DO - 10.3174/ajnr.A1623 ID - Carpenter2009 ER - TY - JOUR AU - Solinas, C. AU - Porcu, M. AU - Silva, P. PY - 2018 DA - 2018// TI - Cancer immunotherapy-associated hypophysitis JO - Semin Oncol VL - 45 UR - https://doi.org/10.1053/j.seminoncol.2018.09.002 DO - 10.1053/j.seminoncol.2018.09.002 ID - Solinas2018 ER - TY - JOUR AU - Lee, H. AU - Hodi, F. S. AU - Giobbie-Hurder, A. PY - 2017 DA - 2017// TI - Characterization of thyroid disorders in patients receiving immune checkpoint inhibition therapy JO - Cancer Immunol Res VL - 5 UR - https://doi.org/10.1158/2326-6066.CIR-17-0208 DO - 10.1158/2326-6066.CIR-17-0208 ID - Lee2017 ER - TY - JOUR AU - Bacanovic, S. a. r. a. AU - Burger, I. r. e. n. e. A. AU - Stolzmann, P. a. u. l. AU - Hafner, J. ü. r. g. AU - Huellner, M. a. r. t. i. n. W. PY - 2015 DA - 2015// TI - Ipilimumab-Induced Adrenalitis JO - Clinical Nuclear Medicine VL - 40 UR - https://doi.org/10.1097/RLU.0000000000000887 DO - 10.1097/RLU.0000000000000887 ID - Bacanovic2015 ER - TY - JOUR AU - Chuzi, S. AU - Tavora, F. AU - Cruz, M. PY - 2017 DA - 2017// TI - Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis JO - Cancer Manag Res VL - 9 UR - https://doi.org/10.2147/CMAR.S136818 DO - 10.2147/CMAR.S136818 ID - Chuzi2017 ER - TY - JOUR AU - Naidoo, J. AU - Wang, X. AU - Woo, K. M. PY - 2017 DA - 2017// TI - Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2016.68.2005 DO - 10.1200/JCO.2016.68.2005 ID - Naidoo2017 ER - TY - JOUR AU - Nishino, M. i. z. u. k. i. AU - Giobbie-Hurder, A. n. i. t. a. AU - Hatabu, H. i. r. o. t. o. AU - Ramaiya, N. i. k. h. i. l. H. AU - Hodi, F. S. t. e. p. h. e. n. PY - 2016 DA - 2016// TI - Incidence of Programmed Cell Death 1 Inhibitor–Related Pneumonitis in Patients With Advanced Cancer JO - JAMA Oncology VL - 2 UR - https://doi.org/10.1001/jamaoncol.2016.2453 DO - 10.1001/jamaoncol.2016.2453 ID - Nishino2016 ER - TY - JOUR AU - Khunger, M. AU - Rakshit, S. AU - Pasupuleti, V. PY - 2017 DA - 2017// TI - Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials JO - Chest VL - 152 UR - https://doi.org/10.1016/j.chest.2017.04.177 DO - 10.1016/j.chest.2017.04.177 ID - Khunger2017 ER - TY - JOUR AU - Nishino, M. AU - Ramaiya, N. H. AU - Awad, M. M. PY - 2016 DA - 2016// TI - PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course JO - Clin Cancer Res VL - 22 UR - https://doi.org/10.1158/1078-0432.CCR-16-1320 DO - 10.1158/1078-0432.CCR-16-1320 ID - Nishino2016 ER - TY - JOUR AU - Delaunay, M. AU - Cadranel, J. AU - Lusque, A. PY - 2017 DA - 2017// TI - Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients JO - Eur Respir J VL - 10 UR - https://doi.org/10.1183/13993003 DO - 10.1183/13993003 ID - Delaunay2017 ER - TY - JOUR AU - Montaudié, H. AU - Pradelli, J. AU - Passeron, T. AU - Lacour, J. -. P. AU - Leroy, S. PY - 2016 DA - 2016// TI - Pulmonary sarcoid-like granulomatosis induced by nivolumab JO - British Journal of Dermatology VL - 176 UR - https://doi.org/10.1111/bjd.14808 DO - 10.1111/bjd.14808 ID - Montaudié2016 ER - TY - JOUR AU - Johnson, D. B. AU - Balko, J. M. AU - Compton, M. L. PY - 2016 DA - 2016// TI - Fulminant myocarditis with combination immune checkpoint blockade JO - N Engl J Med VL - 375 UR - https://doi.org/10.1056/NEJMoa1609214 DO - 10.1056/NEJMoa1609214 ID - Johnson2016 ER - TY - JOUR AU - Loffler, A. I. AU - Salerno, M. PY - 2018 DA - 2018// TI - Cardiac MRI for the evaluation of oncologic cardiotoxicity JO - J Nucl Cardiol VL - 25 UR - https://doi.org/10.1007/s12350-018-1293-9 DO - 10.1007/s12350-018-1293-9 ID - Loffler2018 ER - TY - JOUR AU - Altan, M. AU - Toki, M. I. AU - Gettinger, S. N. PY - 2019 DA - 2019// TI - Immune checkpoint inhibitor-associated pericarditis JO - J Thorac Oncol VL - 14 UR - https://doi.org/10.1016/j.jtho.2019.02.026 DO - 10.1016/j.jtho.2019.02.026 ID - Altan2019 ER - TY - STD TI - Crout TM, Lennep DS, Kishore S, Majithia V (2019) Systemic vasculitis associated with immune check point inhibition: analysis and review. Curr Rheumatol Rep 21:28. https://doi.org/10.1007/s11926-019-0828-7 ID - ref70 ER - TY - JOUR AU - Psimaras, D. PY - 2018 DA - 2018// TI - Neuromuscular complications of immune checkpoint inhibitors JO - Presse Med VL - 47 UR - https://doi.org/10.1016/j.lpm.2018.10.009 DO - 10.1016/j.lpm.2018.10.009 ID - Psimaras2018 ER - TY - JOUR AU - Gandhi, L. AU - Rodríguez-Abreu, D. AU - Gadgeel, S. PY - 2018 DA - 2018// TI - Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer JO - N Engl J Med VL - 378 UR - https://doi.org/10.1056/NEJMoa1801005 DO - 10.1056/NEJMoa1801005 ID - Gandhi2018 ER - TY - JOUR AU - Meléndez, B. á. r. b. a. r. a. AU - Van Campenhout, C. l. a. u. d. e. AU - Rorive, S. a. n. d. r. i. n. e. AU - Remmelink, M. y. r. i. a. m. AU - Salmon, I. s. a. b. e. l. l. e. AU - D’Haene, N. i. c. k. y. PY - 2018 DA - 2018// TI - Methods of measurement for tumor mutational burden in tumor tissue JO - Translational Lung Cancer Research VL - 7 UR - https://doi.org/10.21037/tlcr.2018.08.02 DO - 10.21037/tlcr.2018.08.02 ID - Meléndez2018 ER - TY - JOUR AU - Samstein, R. M. AU - Lee, C. H. AU - Shoushtari, A. N. PY - 2019 DA - 2019// TI - Tumor mutational load predicts survival after immunotherapy across multiple cancer types JO - Nat Genet VL - 51 UR - https://doi.org/10.1038/s41588-018-0312-8 DO - 10.1038/s41588-018-0312-8 ID - Samstein2019 ER - TY - JOUR AU - Le, D. T. AU - Durham, J. N. AU - Smith, K. N. PY - 2017 DA - 2017// TI - Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade JO - Science VL - 357 UR - https://doi.org/10.1126/science.aan6733 DO - 10.1126/science.aan6733 ID - Le2017 ER - TY - JOUR AU - Salem, M. E. AU - Puccini, A. AU - Grothey, A. PY - 2018 DA - 2018// TI - Landscape of tumor mutation load, mismatch repair deficiency, and PD-L1 expression in a large patient cohort of gastrointestinal cancers JO - Mol Cancer Res VL - 16 UR - https://doi.org/10.1158/1541-7786 DO - 10.1158/1541-7786 ID - Salem2018 ER - TY - STD TI - Oble DA, Loewe R, Yu P, Mihm MC Jr (2009) Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immun 9:3. PMCID: PMC2935762 ID - ref77 ER - TY - JOUR AU - Romagnoli, G. l. o. r. i. a. AU - Wiedermann, M. e. i. k. e. AU - Hübner, F. r. i. e. d. e. r. i. k. e. AU - Wenners, A. n. t. o. n. i. a. AU - Mathiak, M. i. c. a. e. l. a. AU - Röcken, C. h. r. i. s. t. o. p. h. AU - Maass, N. i. c. o. l. a. i. AU - Klapper, W. o. l. f. r. a. m. AU - Alkatout, I. b. r. a. h. i. m. PY - 2017 DA - 2017// TI - Morphological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) to Investigate Invasive Breast Cancer Immunogenicity, Reveal Lymphocytic Networks and Help Relapse Prediction: A Retrospective Study JO - International Journal of Molecular Sciences VL - 18 UR - https://doi.org/10.3390/ijms18091936 DO - 10.3390/ijms18091936 ID - Romagnoli2017 ER - TY - STD TI - Kwak Y, Koh J, Kim DW, Kang SB, Kim WH, Lee HS (2016) Immunoscore encompassing CD3+ and CD8+ T cell densities in distant metastasis is a robust prognostic marker for advanced colorectal cancer. Oncotarget 7:81778–81790. https://doi.org/10.18632/oncotarget.13207 ID - ref79 ER - TY - JOUR AU - Sun, R. AU - Limkin, E. J. AU - Vakalopoulou, M. PY - 2018 DA - 2018// TI - A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study JO - Lancet Oncol VL - 19 UR - https://doi.org/10.1016/S1470-2045(18)30413-3 DO - 10.1016/S1470-2045(18)30413-3 ID - Sun2018 ER - TY - JOUR AU - Heskamp, S. AU - Hobo, W. AU - Molkenboer-Kuenen, J. D. PY - 2015 DA - 2015// TI - Noninvasive imaging of tumor PD-L1 expression using radiolabeled anti-PD-L1 antibodies JO - Cancer Res VL - 75 UR - https://doi.org/10.1158/0008-5472.CAN-14-3477 DO - 10.1158/0008-5472.CAN-14-3477 ID - Heskamp2015 ER - TY - JOUR AU - Chatterjee, S. AU - Lesniak, W. G. AU - Gabrielson, M. PY - 2016 DA - 2016// TI - A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors JO - Oncotarget VL - 7 UR - https://doi.org/10.18632/oncotarget.7143 DO - 10.18632/oncotarget.7143 ID - Chatterjee2016 ER - TY - JOUR AU - Bensch, F. AU - Veen, E. L. AU - Lub-de Hooge, M. N. PY - 2018 DA - 2018// TI - (89)Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer JO - Nat Med VL - 24 UR - https://doi.org/10.1038/s41591-018-0255-8 DO - 10.1038/s41591-018-0255-8 ID - Bensch2018 ER - TY - JOUR AU - Gettinger, S. c. o. t. t. N. AU - Horn, L. e. o. r. a. AU - Gandhi, L. e. e. n. a. AU - Spigel, D. a. v. i. d. R. AU - Antonia, S. c. o. t. t. J. AU - Rizvi, N. a. i. y. e. r. A. AU - Powderly, J. o. h. n. D. AU - Heist, R. e. b. e. c. c. a. S. AU - Carvajal, R. i. c. h. a. r. d. D. AU - Jackman, D. a. v. i. d. M. AU - Sequist, L. e. c. i. a. V. AU - Smith, D. a. v. i. d. C. AU - Leming, P. h. i. l. i. p. AU - Carbone, D. a. v. i. d. P. AU - Pinder-Schenck, M. a. r. y. C. AU - Topalian, S. u. z. a. n. n. e. L. AU - Hodi, F. S. t. e. p. h. e. n. AU - Sosman, J. e. f. f. r. e. y. A. AU - Sznol, M. a. r. i. o. AU - McDermott, D. a. v. i. d. F. AU - Pardoll, D. r. e. w. M. AU - Sankar, V. i. n. d. i. r. a. AU - Ahlers, C. h. r. i. s. t. o. p. h. M. AU - Salvati, M. a. r. k. AU - Wigginton, J. o. n. M. AU - Hellmann, M. a. t. t. h. e. w. D. AU - Kollia, G. e. o. r. g. i. a. D. AU - Gupta, A. s. h. o. k. K. AU - Brahmer, J. u. l. i. e. R. PY - 2015 DA - 2015// TI - Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer JO - Journal of Clinical Oncology VL - 33 UR - https://doi.org/10.1200/JCO.2014.58.3708 DO - 10.1200/JCO.2014.58.3708 ID - Gettinger2015 ER - TY - JOUR AU - Nishino, M. i. z. u. k. i. AU - Dahlberg, S. u. z. a. n. n. e. E. AU - Adeni, A. n. i. k. a. E. AU - Lydon, C. h. r. i. s. t. i. n. e. A. AU - Hatabu, H. i. r. o. t. o. AU - Jänne, P. a. s. i. A. AU - Hodi, F. S. t. e. p. h. e. n. AU - Awad, M. a. r. k. M. PY - 2017 DA - 2017// TI - Tumor Response Dynamics of Advanced Non–small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome JO - Clinical Cancer Research VL - 23 UR - https://doi.org/10.1158/1078-0432.CCR-17-1434 DO - 10.1158/1078-0432.CCR-17-1434 ID - Nishino2017 ER - TY - JOUR AU - Katz, S. h. a. r. y. n. I. AU - Hammer, M. a. r. k. AU - Bagley, S. t. e. p. h. e. n. J. AU - Aggarwal, C. h. a. r. u. AU - Bauml, J. o. s. h. u. a. M. AU - Thompson, J. e. f. f. r. e. y. C. AU - Nachiappan, A. r. u. n. C. AU - Simone, C. h. a. r. l. e. s. B. AU - Langer, C. o. r. e. y. J. PY - 2018 DA - 2018// TI - Radiologic Pseudoprogression during Anti–PD-1 Therapy for Advanced Non–Small Cell Lung Cancer JO - Journal of Thoracic Oncology VL - 13 UR - https://doi.org/10.1016/j.jtho.2018.04.010 DO - 10.1016/j.jtho.2018.04.010 ID - Katz2018 ER -